Latest news with #MalcolmKendall
Time of India
3 days ago
- Business
- Time of India
Mapmygenome acquires Canadian CRO Microbiome Insights
HYDERABAD: AI-driven genomics and personalised health player Mapmygenome has acquired Canadian microbial sequencing player Microbiome Insights. The acquisition includes the CAP-accredited (College of American Pathologists) Canadian laboratory of Microbiome Insights as well as its intellectual property. Though the Hyderabad-based Mapmygenome did not divulge the size of acquisition, its founder & CEO Anu Acharya confirmed that it had acquired 100% stake in the 10-year-old Canadian company. She said the acquisition would boost Mapmygenome's scientific prowess and enable its global expansion. Microbiome Insights, which has supported over 600 global clients with more than 1,000 cutting-edge microbiome studies, is a leading partner for academic, clinical, and industry researchers. It was founded by renowned global experts such as Dr Brett Finlay, Dr William Mohn, and Malcolm Kendall. While post-acquisition Microbiome Insights will maintain its role as a premier CRO (clinical research organisation), Mapmygenome said it will roll out its integrated genomics and microbiome testing services to North America to make holistic, data-driven health solutions more accessible. 'The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Esta nueva alarma con cámara es casi regalada en Sarandí (ver precio) Verisure Undo We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors,' said Acharya. She said the buy will accelerate the company's North American footprint, aligning with Mapmygenome's strategic vision of growth through targeted acquisitions as it works towards its listing on the Indian bourses later this year. Microbiome Insights CEO Malcolm Kendall said the deal would provide the company the resources and capabilities to offer higher quality services to clients and accelerate growth. Microbiome Insights offers end-to-end microbiome sequencing and comprehensive bioinformatic analysis for sectors such as pharma, biotech, nutrition, cosmetics, agriculture as well as government institutions and has enabled over 1,000 studies. These range from basic research to clinical trials, and biomarker discovery to machine-learning based modelling. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
The Hindu
3 days ago
- Business
- The Hindu
MapMyGenome acquires Canada-based Microbiome Insights
Hyderabad-based genomics and microbiome testing firm MapMyGenome has acquired Canadian company Microbiome Insights, a globally recognised leader in microbial sequencing, in a move aimed at expanding its global presence and deepening scientific capabilities. The acquisition includes Microbiome Insights' CAP-accredited laboratory in Canada, along with its intellectual property portfolio. This development will strengthen MapMyGenome's research and clinical offerings, particularly in the fields of metagenomics, transcriptomics, and targeted metabolomics. It also marks the company's formal entry into the North American market with plans to roll out integrated genomics and microbiome testing services across the region, said a release. MapMyGenome CEO and founder Anu Acharya described the acquisition as a major milestone in the company's global strategy. 'The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. It accelerates our North American footprint, aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year,' she said. Malcolm Kendall, CEO of Microbiome Insights, called the merger an opportunity to enhance service quality and broaden global reach. 'Joining forces with MapMyGenome provides the resources and capabilities to offer higher quality services to our clients and accelerate growth. The combination of their expertise in AI-driven genomics solutions and our deep microbiome expertise will result in a new standard of cutting-edge services for clients worldwide,' he said.
Cision Canada
3 days ago
- Business
- Cision Canada
Mapmygenome cements global leadership in Genomics with strategic acquisition of Canada's Microbiome Insights
HYDERABAD, India and VANCOUVER, BC, May 29, 2025 /CNW/ -- Mapmygenome, an AI-driven leader in genomics and personalized health, announced the strategic acquisition of Microbiome Insights, a global leader in microbial sequencing. The acquisition includes Microbiome Insights' CAP-accredited Canadian laboratory and rich intellectual property, boosting Mapmygenome's scientific prowess and enabling its global expansion. Having supported over 600 global clients with 1,000+ cutting-edge microbiome studies, Microbiome Insights is a leading partner for academic, clinical, and industry researchers. Its founders, Dr. Brett Finlay, Dr. William Mohn, and Malcolm Kendall, are recognized global experts. Microbiome Insights will maintain its role as a premier CRO, empowering global research. Simultaneously, Mapmygenome will introduce its integrated genomics and microbiome testing services to North America, making holistic, data-driven health solutions more accessible. "The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors," declared Anu Acharya, Founder and CEO of Mapmygenome. "This accelerates our North American footprint aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year" "Joining forces with Mapmygenome, provides the resources and capabilities to offer higher quality services to our clients and accelerate growth. The combination of their expertise in AI-driven genomics solutions and our deep microbiome expertise will result in a new standard of cutting-edge services for clients worldwide," said Malcolm Kendall, CEO of Microbiome Insights. Financial terms were not disclosed. About Mapmygenome: Founded a decade ago, we are a leading genomics company driven by pioneering research and a vision for preventive healthcare. We harness AI-driven genomic and microbiome testing to deliver personalized health solutions, with offerings like at-home DNA tests for proactive health and longevity. For healthcare providers, our diagnostic genomic tests are conducted in a CAP-accredited lab, ensuring high accuracy, complemented by genetic counseling. About Microbiome Insights: We are a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatic analysis. Collaborating with pharma, biotech, nutrition, cosmetic, and agriculture clients, alongside leading academic and government institutions, we've supported over 1,000 studies, from basic research to clinical trials, and biomarker discovery to machine-learning based modeling.
Business Standard
3 days ago
- Business
- Business Standard
Mapmygenome cements global leadership in Genomics with strategic acquisition of Canada's Microbiome Insights
PRNewswire Hyderabad (Telangana) [India] / Vancouver (British Columbia) [Canada], May 29: Mapmygenome, an AI-driven leader in genomics and personalized health, announced the strategic acquisition of Microbiome Insights, a global leader in microbial sequencing. The acquisition includes Microbiome Insights' CAP-accredited Canadian laboratory and rich intellectual property, boosting Mapmygenome's scientific prowess and enabling its global expansion. Having supported over 600 global clients with 1,000+ cutting-edge microbiome studies, Microbiome Insights is a leading partner for academic, clinical, and industry researchers. Its founders, Dr. Brett Finlay, Dr. William Mohn, and Malcolm Kendall, are recognized global experts. Microbiome Insights will maintain its role as a premier CRO, empowering global research. Simultaneously, Mapmygenome will introduce its integrated genomics and microbiome testing services to North America, making holistic, data-driven health solutions more accessible. "The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors," declared Anu Acharya, Founder and CEO of Mapmygenome. "This accelerates our North American footprint aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year" "Joining forces with Mapmygenome, provides the resources and capabilities to offer higher quality services to our clients and accelerate growth. The combination of their expertise in AI-driven genomics solutions and our deep microbiome expertise will result in a new standard of cutting-edge services for clients worldwide," said Malcolm Kendall, CEO of Microbiome Insights. Financial terms were not disclosed. About Mapmygenome: Founded a decade ago, we are a leading genomics company driven by pioneering research and a vision for preventive healthcare. We harness AI-driven genomic and microbiome testing to deliver personalized health solutions, with offerings like at-home DNA tests for proactive health and longevity. For healthcare providers, our diagnostic genomic tests are conducted in a CAP-accredited lab, ensuring high accuracy, complemented by genetic counseling. About Microbiome Insights: We are a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatic analysis. Collaborating with pharma, biotech, nutrition, cosmetic, and agriculture clients, alongside leading academic and government institutions, we've supported over 1,000 studies, from basic research to clinical trials, and biomarker discovery to machine-learning based modeling.
Entrepreneur
3 days ago
- Business
- Entrepreneur
Mapmygenome Acquires Microbiome Insights to Boost Global Genomics Reach
The acquisition also enables Mapmygenome to introduce its integrated genomics and microbiome testing to North America, providing accessible, data-driven health solutions across borders. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. In a move set to redefine personalised health and microbial research, Mapmygenome, an AI-driven leader in genomics, has announced the strategic acquisition of Microbiome Insights, a Canadian pioneer in microbiome sequencing. The deal includes Microbiome Insights' CAP-accredited laboratory and a valuable portfolio of intellectual property, significantly enhancing Mapmygenome's scientific capabilities and global reach. With over 1,000 studies completed for 600+ clients globally, Microbiome Insights is a trusted partner for academic, clinical, and industrial research. The company, co-founded by microbiome experts Dr Brett Finlay, Dr William Mohn, and Malcolm Kendall, will continue to operate as a premier contract research organization (CRO), supporting innovation in microbial science. "The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area," said Anu Acharya, Founder and CEO of Mapmygenome. "We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors. This accelerates our North American footprint, aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year." The acquisition also enables Mapmygenome to introduce its integrated genomics and microbiome testing to North America, providing accessible, data-driven health solutions across borders. "Joining forces with Mapmygenome provides the resources and capabilities to offer higher quality services to our clients and accelerate growth," said Malcolm Kendall, CEO of Microbiome Insights. "Our combined strengths will deliver a new standard of cutting-edge services for clients worldwide." Financial terms of the deal were not disclosed. The partnership marks a pivotal moment in the convergence of genomics, microbiome science, and AI for global health innovation.
